Hikma Pharmaceuticals PLC Annual report 2010 notes to tHe ConsoLIdAted FInAnCIALstAtements Continued 30. derIvAtIve FInAnCIAL Instruments Currency derivatives The Group utilises currency derivatives to hedge significant future transactions and cash flows.
The Group is party to a variety of foreign currency forward contracts and options in the management of its exchange rate exposures.
The instruments purchased are primarily denominated in the currencies of the Groups principal markets.
At the balance sheet date, the total notional amount of outstanding forward foreign exchange contracts that the Group was committed to, have been translated at 31 December exchange rates as below.
2010 2009 $000 $000 Foreign exchange forward contracts and options euro 4,780 These arrangements are designed to address significant exchange exposures.
At 31 December 2010 the fair value of the Groups currency derivatives some of which were designated as effective cash flow hedges was an asset of USD 83,000 2009 USD nil.
The movement in fair value in the year resulted in a gain of USD 83,000 2009: USD 382,000 net loss which has been reflected in equity.
These amounts were based on market values of equivalent instruments at the balance sheet date.
The fair value of the currency derivatives which were designated as ineffective cash flow hedges was an asset of USD 8,000 2009 Assets of: nil held at fair value through profit and loss.
The movement in fair value in the year resulted in a gain of USD 8,000 has been recognised in the statement of comprehensive income for the year ended 31 December 2010 2009: nil in respect of such derivatives.
The Group believes that the effect on the value of cash flow hedges of currency and interest rate fluctuations is not significant and will not materially affect the financial position of the Group.
Interest rate swaps The Group uses interest rate swaps to manage its exposure to interest rate movements on its bank borrowings.
These contracts have nominal values of USD 45.4 million 2009: USD 34.4 million and have fixed interest payments at rates ranging from 1.91% to 4.75% 2009: 1.91% to 4.75 for periods up until 2016 and have floating interest receipts at LIBOR or EURIBOR.
The fair value of swaps entered into by the Group is estimated as a liability of USD 1,287,000 2009: liability of USD 932,000.
These amounts are based on market values provided by the banks that originated the swaps and are based on equivalent instruments at the balance sheet date.
Some of these interest rate swaps are designated as effective cash flow hedges and the movement in fair value totalling a loss of USD 339,000 2009: USD gain of 180,000 has been reflected in equity.
The remaining outstanding interest rate swaps that the Group was committed to at the year end are held at fair value through profit and loss.
The movement in fair value in the year resulted in a loss of USD 16,000 which has been recognised in the statement of comprehensive income for the year ended 31 December 2010 2009: loss of 216,000 in respect of such derivatives.
The Group believes that the effect on the value of interest rate swaps by interest rate fluctuations will not materially affect the financial position of the Group.
